Literature DB >> 23274591

Haplotype analysis and ancient origin of the BRCA1 c.4035delA Baltic founder mutation.

Ramūnas Janavičius1, Vilius Rudaitis, Bing-Jian Feng, Silvija Ozolina, Laimonas Griškevičius, David Goldgar, Laima Tihomirova.   

Abstract

Uncertainty exists about the origin of BRCA1 c.4035delA mutation which is prevalent in Baltic countries, with the highest frequency being in Lithuania (53% of all BRCA1 mutations), although formal founder mutation analysis by haplotype has not yet been undertaken. In this study we genotyped 78 unrelated BRCA1 c.4035delA mutation carriers families from Lithuania, Latvia, Poland and Russia. The results from the haplotype analyses were used to estimate the age of the mutation. Using maximum likelihood methods we estimated that the mutation arose approximately 1550 years (62 generations of 25 years) ago (ca. 5th century) somewhere in the present territory of Lithuania, in the area inhabited by ancient Baltic tribes at that time. Our results show that this mutation gradually entered the gene pool in the neighboring countries.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23274591     DOI: 10.1016/j.ejmg.2012.12.007

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  3 in total

1.  Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation.

Authors:  Yuya Kobayashi; Shan Yang; Keith Nykamp; John Garcia; Stephen E Lincoln; Scott E Topper
Journal:  Genome Med       Date:  2017-02-06       Impact factor: 11.117

2.  The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases.

Authors:  Gisella Figlioli; Anders Kvist; Emma Tham; Jana Soukupova; Petra Kleiblova; Taru A Muranen; Nadine Andrieu; Jacopo Azzollini; Judith Balmaña; Alicia Barroso; Javier Benítez; Birgitte Bertelsen; Ana Blanco; Bernardo Bonanni; Åke Borg; Joan Brunet; Daniele Calistri; Mariarosaria Calvello; Stepan Chvojka; Laura Cortesi; Esther Darder; Jesús Del Valle; Orland Diez; Séverine Eon-Marchais; Florentia Fostira; Francesca Gensini; Claude Houdayer; Marketa Janatova; Johanna I Kiiski; Irene Konstantopoulou; Katerina Kubelka-Sabit; Conxi Lázaro; Fabienne Lesueur; Siranoush Manoukian; Ruta Marcinkute; Ugnius Mickys; Virginie Moncoutier; Aleksander Myszka; Tu Nguyen-Dumont; Finn Cilius Nielsen; Rimvydas Norvilas; Edith Olah; Ana Osorio; Laura Papi; Bernard Peissel; Ana Peixoto; Dijana Plaseska-Karanfilska; Timea Pócza; Maria Rossing; Vilius Rudaitis; Marta Santamariña; Catarina Santos; Snezhana Smichkoska; Melissa C Southey; Dominique Stoppa-Lyonnet; Manuel Teixeira; Therese Törngren; Angela Toss; Miguel Urioste; Ana Vega; Zdenka Vlckova; Drakoulis Yannoukakos; Valentina Zampiga; Zdenek Kleibl; Paolo Radice; Heli Nevanlinna; Hans Ehrencrona; Ramunas Janavicius; Paolo Peterlongo
Journal:  Cancers (Basel)       Date:  2020-01-26       Impact factor: 6.639

3.  Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?

Authors:  Tu Nguyen-Dumont; Pawel Karpinski; Maria M Sasiadek; Hayane Akopyan; Jason A Steen; Derrick Theys; Fleur Hammet; Helen Tsimiklis; Daniel J Park; Bernard J Pope; Ryszard Slezak; Agnieszka Stembalska; Karolina Pesz; Nataliya Kitsera; Aleksandra Siekierzynska; Melissa C Southey; Aleksander Myszka
Journal:  Genet Res (Camb)       Date:  2020-08-10       Impact factor: 1.588

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.